PL2320927T3 - Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD - Google Patents
Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMDInfo
- Publication number
- PL2320927T3 PL2320927T3 PL09780378T PL09780378T PL2320927T3 PL 2320927 T3 PL2320927 T3 PL 2320927T3 PL 09780378 T PL09780378 T PL 09780378T PL 09780378 T PL09780378 T PL 09780378T PL 2320927 T3 PL2320927 T3 PL 2320927T3
- Authority
- PL
- Poland
- Prior art keywords
- psd
- nmda receptor
- potent inhibitors
- modified peptides
- receptor interaction
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 230000010799 Receptor Interactions Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108091005601 modified peptides Proteins 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7929008P | 2008-07-09 | 2008-07-09 | |
| EP08160017 | 2008-07-09 | ||
| US10793308P | 2008-10-23 | 2008-10-23 | |
| PCT/EP2009/058752 WO2010004003A2 (en) | 2008-07-09 | 2009-07-09 | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| EP09780378.7A EP2320927B1 (en) | 2008-07-09 | 2009-07-09 | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2320927T3 true PL2320927T3 (pl) | 2016-02-29 |
Family
ID=40202958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09780378T PL2320927T3 (pl) | 2008-07-09 | 2009-07-09 | Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9241967B2 (pl) |
| EP (1) | EP2320927B1 (pl) |
| DK (1) | DK2320927T3 (pl) |
| ES (1) | ES2542522T3 (pl) |
| PL (1) | PL2320927T3 (pl) |
| WO (1) | WO2010004003A2 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2440231T (pt) | 2009-06-10 | 2020-01-08 | Nono Inc | Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos |
| CA2765169C (en) | 2009-06-10 | 2019-06-18 | Nono Inc. | Model systems and treatment regimes for treatment of neurological disease |
| KR102046830B1 (ko) * | 2011-05-13 | 2019-11-20 | 코벤하븐스 유니버시테트 | 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제 |
| US9139615B2 (en) | 2011-05-13 | 2015-09-22 | University Of Copenhagen | High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain |
| HRP20220519T1 (hr) | 2011-06-24 | 2022-05-27 | Nono Inc. | Kombinacijska terapija ishemije |
| PL3074032T3 (pl) * | 2013-12-01 | 2019-06-28 | University Of Copenhagen | Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95 |
| UA123820C2 (uk) * | 2014-05-28 | 2021-06-09 | Ноно Інк. | Хлоридна сіль пептиду tat-nr2b9c |
| US11229675B2 (en) | 2016-04-27 | 2022-01-25 | Biocells (Beijing) Biotech Co., Ltd. | Therapeutic peptides for excitatory neurotoxicity-related injuries |
| CN108640974B (zh) * | 2018-05-19 | 2021-07-06 | 上海市第一妇婴保健院 | 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体 |
| EP4106818A4 (en) * | 2020-02-19 | 2024-03-20 | NoNO Inc. | Inhibition of reperfusion injury with a psd-95 inhibitor |
| EP4000598A1 (en) | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| TW202306965A (zh) | 2021-05-12 | 2023-02-16 | 哥本哈根大學 | Ｐｓｄ－９５抑制劑及其用途 |
| WO2024149230A1 (zh) * | 2023-01-09 | 2024-07-18 | 北京拓界生物医药科技有限公司 | 一种神经保护性psd-95多肽抑制剂及其应用 |
| CN117903259B (zh) * | 2023-09-07 | 2024-09-20 | 湖南中晟全肽生物科技股份有限公司 | 一种psd-95抑制剂及其用途 |
| CN117164725B (zh) * | 2023-09-07 | 2024-05-10 | 湖南中晟全肽生物科技股份有限公司 | 一种突触后密度蛋白-95抑制剂多肽 |
| WO2025051130A1 (zh) * | 2023-09-07 | 2025-03-13 | 湖南中晟全肽生物科技股份有限公司 | 作为神经保护剂的药用化合物及其应用 |
| WO2025215348A1 (en) * | 2024-04-08 | 2025-10-16 | The Boots Company Plc | Skin wound treatment |
| TW202607013A (zh) * | 2024-07-08 | 2026-02-16 | 大陸商福建盛迪醫藥有限公司 | 一種包含ｐｓｄ－９５多肽抑制劑的醫藥組成物及其製備方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| AU2002321903A1 (en) * | 2001-08-03 | 2003-02-24 | Arbor Vita Corporation | Molecular interactions in cells |
| WO2007140282A1 (en) | 2006-05-24 | 2007-12-06 | Peg Biosciences | Peg linker compounds and biologically active conjugates thereof |
| CA2657665C (en) | 2006-07-11 | 2015-06-02 | Arbor Vita Corporation | Method and compositions for treating stroke with fever |
| PT2440231T (pt) * | 2009-06-10 | 2020-01-08 | Nono Inc | Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos |
| US9241970B2 (en) * | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
-
2009
- 2009-07-09 PL PL09780378T patent/PL2320927T3/pl unknown
- 2009-07-09 ES ES09780378.7T patent/ES2542522T3/es active Active
- 2009-07-09 DK DK09780378.7T patent/DK2320927T3/en active
- 2009-07-09 WO PCT/EP2009/058752 patent/WO2010004003A2/en not_active Ceased
- 2009-07-09 EP EP09780378.7A patent/EP2320927B1/en active Active
- 2009-07-09 US US13/002,638 patent/US9241967B2/en active Active
-
2015
- 2015-12-16 US US14/971,432 patent/US9902754B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2320927B1 (en) | 2015-06-10 |
| EP2320927A2 (en) | 2011-05-18 |
| US20110178022A1 (en) | 2011-07-21 |
| WO2010004003A2 (en) | 2010-01-14 |
| US20160176924A1 (en) | 2016-06-23 |
| US9241967B2 (en) | 2016-01-26 |
| US9902754B2 (en) | 2018-02-27 |
| ES2542522T3 (es) | 2015-08-06 |
| WO2010004003A3 (en) | 2010-05-14 |
| DK2320927T3 (en) | 2015-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246710A0 (en) | Antibodies specific for claudin 6 (cldn6) | |
| ZA201102406B (en) | Pharmaceutical composition for modified release | |
| ZA201001798B (en) | Composition and methods for using proislet peptides and analogs thereof | |
| SG2014011365A (en) | Novel antibody formulation | |
| IL212551A0 (en) | Cxcr4 receptor compounds | |
| DK2374798T3 (da) | Benzazepin-derivat til anvendelse som vasopressin-antagonister | |
| ZA201001252B (en) | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect | |
| IL194494A0 (en) | Thiazolyldihydrocyclopentapyrazoles for use as pi3-kinase inhibitors | |
| SI2151428T1 (sl) | Postopek za pripravo agomelatina | |
| ZA201103347B (en) | Pharmaceutical aerosol composition | |
| EP2478001A4 (en) | BENEFICIAL PEPTIDE COMPOUNDS OF MU OPIACEOUS RECEPTOR | |
| GB2470495B (en) | Oxazolidine derivatives as NMDA antagonists | |
| GB0800730D0 (en) | Balum splitter | |
| IL208543A0 (en) | Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopetidases | |
| IL211996A0 (en) | Process for the preparation of substituted phenylalanines | |
| EP2041295A4 (en) | PROCESS FOR ARBITRARY PEPTIDESYNTHESIS | |
| GB0710858D0 (en) | Methods for the synthesis of peptides | |
| HU0600036V0 (en) | Stand construction for packaging | |
| GB0805807D0 (en) | Novel pharmaceutical compositions | |
| GB0804485D0 (en) | Novel pharmaceutical compositions | |
| TWM339363U (en) | Structure for powder gushing | |
| SMT202100059T1 (it) | Composizione farmaceutica per il rilascio modificato |